Señales en vivo de RXDX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 jun 2023 @ 16:00):

Stats
Volumen de hoy	1.79M
Volumen promedio	1.22M
Capitalización de mercado	9.56B
EPS	$-0.860 ( 2023-08-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-56.47
ATR14	$2.40 (1.20%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-16	Hendrix Martin	Sell	2 071	Common Stock
2023-06-16	Hendrix Martin	Sell	40 000	Stock Option (right to buy)
2023-06-16	Hendrix Martin	Sell	20 500	Stock Option (right to buy)
2023-06-16	Laur James	Sell	2 071	Common Stock
2023-06-16	Laur James	Sell	40 000	Stock Option (right to buy)

INSIDER POWER
-86.79
Last 100 transactions
Buy: 394 552 \| Sell: 5 154 734

Volumen Correlación

Largo: 0.34 (neutral)

Corto: -0.25 (neutral)

Signal:(84.036) Neutral

Prometheus Biosciences, Correlación

10 Correlaciones Más Positivas
KDNY	0.976
KRYS	0.968
AVEO	0.965
ITRI	0.96
BSQR	0.956
PPC	0.953
BLU	0.952
BWMX	0.951
XLRN	0.951
PCTI	0.951

10 Correlaciones Más Negativas
SMSI	-0.971
HLXA	-0.95
TWKS	-0.946
UPLD	-0.946
PEAR	-0.938
VORB	-0.935
LUNG	-0.933
THTX	-0.933
ENPH	-0.932
XFOR	-0.931

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prometheus Biosciences, Correlación - Moneda/Commodity

0.34
( neutral )

0.56
( weak )

-0.33
( neutral )

-0.18
( neutral )

0.39
( neutral )

0.60
( weak )

Prometheus Biosciences, Finanzas

Annual	2023
Ingresos:	$6.81M
Beneficio Bruto:	$6.81M (100.00 %)
EPS:	$-3.49

FY	2023
Ingresos:	$6.81M
Beneficio Bruto:	$6.81M (100.00 %)
EPS:	$-3.49

FY	2022
Ingresos:	$3.13M
Beneficio Bruto:	$3.13M (100.00 %)
EPS:	$-2.87

FY	2020
Ingresos:	$1.23M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.376

Financial Reports:

No articles found.

Prometheus Biosciences,

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.